Literature DB >> 8396237

Human cells express two differentially spliced forms of topoisomerase II beta mRNA.

S L Davies1, J R Jenkins, I D Hickson.   

Abstract

Screening of a human B-cell cDNA library with a topoisomerase II beta gene-specific probe revealed the presence of two distinct forms of topoisomerase II beta cDNA. One form (designated topoisomerase II beta-1), representing the majority of the clones, would encode the topoisomerase II beta amino acid sequence reported recently [Jenkins, J.R. et al. (1992) Nucleic Acids Res., 20, 5587-5592]. The second form (designated topoisomerase II beta-2) would encode a protein containing an additional 5 amino acids inserted after Valine-23 of the topoisomerase II beta-1 protein sequence. The topoisomerase II beta-1 and beta-2 mRNAs were both widely expressed in human cell lines and tissues. Topoisomerase II beta-2 mRNA was expressed at a lower level than that of the beta-1 form, but the relative expression of the two forms varied in different cell types. Analysis of genomic DNA clones revealed that the two forms of topoisomerase II beta mRNA arose via differential splicing. These data indicate that in addition to the closely related topoisomerase II alpha and beta isozymes, there are two forms of topoisomerase II beta mRNA widely expressed in human cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396237      PMCID: PMC309874          DOI: 10.1093/nar/21.16.3719

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  25 in total

1.  Complete nucleotide sequence and genome organization of a Drosophila transposable genetic element, 297.

Authors:  S Inouye; S Yuki; K Saigo
Journal:  Eur J Biochem       Date:  1986-01-15

2.  Transcription-dependent DNA supercoiling in yeast DNA topoisomerase mutants.

Authors:  S J Brill; R Sternglanz
Journal:  Cell       Date:  1988-07-29       Impact factor: 41.582

3.  Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.

Authors:  F H Drake; J P Zimmerman; F L McCabe; H F Bartus; S R Per; D M Sullivan; W E Ross; M R Mattern; R K Johnson; S T Crooke
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

Review 4.  DNA topoisomerases.

Authors:  J C Wang
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

5.  Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro.

Authors:  Y S Bae; I Kawasaki; H Ikeda; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro.

Authors:  L Yang; M S Wold; J J Li; T J Kelly; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

7.  DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication.

Authors:  S DiNardo; K Voelkel; R Sternglanz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  Cloning of yeast TOP1, the gene encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and DNA topoisomerase II.

Authors:  T Goto; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis.

Authors:  T Uemura; M Tanagida
Journal:  EMBO J       Date:  1986-05       Impact factor: 11.598

10.  In vitro transcription by Xenopus oocytes RNA polymerase III requires a DNA topoisomerase II activity.

Authors:  G C Glikin; D Blangy
Journal:  EMBO J       Date:  1986-01       Impact factor: 11.598

View more
  4 in total

1.  Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.

Authors:  S Houlbrook; C M Addison; S L Davies; J Carmichael; I J Stratford; A L Harris; I D Hickson
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

2.  Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.

Authors:  S L Davies; J Bergh; A L Harris; I D Hickson
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

Authors:  M I Sandri; D Hochhauser; P Ayton; R C Camplejohn; R Whitehouse; H Turley; K Gatter; I D Hickson; A L Harris
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

Review 4.  TOP2B: The First Thirty Years.

Authors:  Caroline A Austin; Ka C Lee; Rebecca L Swan; Mushtaq M Khazeem; Catriona M Manville; Peter Cridland; Achim Treumann; Andrew Porter; Nick J Morris; Ian G Cowell
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.